Studying immune responses to improve Lyme disease diagnosis in children
Studies blood immune responses to help diagnose Lyme disease in children.
Key facts
- Who runs it
- University Children's Hospital, Zurich
- Where
- Zurich, SwitzerlandSee the site
- Trial code
- Registry title
- Borrelia B-cell Diagnostics
- Status
- Recruiting
- People taking part
- 502 people, planned
- Started
- 2 Apr 2024
- Expected to end
- 1 Nov 2028
- Type of study
- Observational, 2 groups
- Treatments tested
- venous blood puncture
- Record updated
- 28 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children seen at the emergency department of University Children's Hospital Zurich whose doctor thinks they may have Lyme disease. It also takes previously healthy children having routine blood tests, as a comparison group.
- Age
- 1 Month to 17 Years
- Sex
- All sexes can join.
- Disease stage
- Children whose doctor is considering Lyme disease as a possible diagnosis. Healthy children can join the comparison group.
Main reasons for not taking part
- A weak immune system present from birth (primary immunodeficiency)
- A weak immune system caused by another illness or treatment (secondary immunodeficiency)
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Patients presenting at the ED with differential diagnosis of LD according to the treating physician
Who cannot take part
- Patients will be excluded in cases of primary or secondary immunodeficiency
Where in Switzerland
- Chidren's Hospital ZurichZurich, SwitzerlandContact: Patrick M Meyer Sauteur, MD PhDTaking people
About the trial
What the trial wants to find out
The investigators propose a single center, prospective observational study in children with Lyme disease (LD), the Borrelia B-cell diagnostics (BRILLIANT) study, to assess the immune response against Borrelia burgdorferi (Bb) with the following main objectives:
Read full original descriptionShow less
1. Development of Bb-specific ASC ELISpot as a new test method for diagnosis of early LD.
There is an urgent unmet clinical need for a better diagnostic tool for early LD, as the current standard two-tier testing has low sensitivity in recently infected patients and may show false positive results in recovered patients due to long-term persistence of antibodies against Bb. The measurement of Bb-specific ASC with the ELISpot assay my has the potential to overcome these issues and to improve diagnosis in early LD. 2. Extensive analysis of the immune response in LD. The immune response in LD is not well understood. Large-scale studies assessing the detailed immune cell subsets/phenotypes present in blood, CSF, or synovial fluid of LD patients with respective manifestations are lacking. 3. Isolation and characterization of causative Bb species. Existing literature suggests that Bb genospecies and/or genotypes may determine virulence and manifestations, but large-scale studies assessing Bb genospecies/genotypes in different manifestation of LD are lacking. 4. Collection of clinical data about symptoms, severity, routine laboratory and diagnostic test results, treatment, and outcome of LD. 5. Biobanking samples for analysis in the future.
Project population
Inclusion criteria: Children, 0-17 years of age, at University Children's Hospital Zurich:
* LD differential diagnosis cohort: Patients presenting at the ED with differential diagnosis of LD according to the treating physician. * Control cohort: Previously healthy patients (HC) with routine blood investigations presenting at the ED or PID outpatient department
Exclusion criteria: Primary or secondary immunodeficiency.
The 2 groups in the trial
- LD_Diff_Diag
LD differential diagnosis cohort: Patients presenting at the ED with differential diagnosis of LD according to the treating physician
Treatment: venous blood puncture
- Heathy_Control
Previously healthy patients (HC) with routine blood investigations presenting at the ED or PID outpatient department
Treatment: venous blood puncture
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Extensive Investigation of Immune Responses Against Borrelia Burgdorferi to Improve Diagnosis of Lyme Disease in Children: an Observational Study (BRILLIANT Study)
- Plain-language title
- Studying immune responses to improve Lyme disease diagnosis in childrenGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 28 April 2026